CRISPR Therapeutics (NASDAQ: CRSP) is a leading gene-editing company focused on developing transformative medicines using CRISPR/Cas9 gene-editing technology. Founded in 2013, the company is headquartered in Boston, Massachusetts, with operations in the US, UK, and Switzerland.
| Attribute | Details | [1]
|-----------|---------| [2]
| Founded | 2013 | [3]
| Headquarters | Boston, Massachusetts, USA | [4]
| IPO | NASDAQ: CRSP (2016) |
| Market Cap | ~$6B (2024) |
| Employees | ~500 |
| Website | crisprtx.com |
CRISPR Therapeutics leverages CRISPR/Cas9 technology for precise gene editing:
| Program | Indication | Modality | Status |
|---|---|---|---|
| CTX110 | B-cell lymphoma | Allogeneic CAR-T | Phase 1/2 |
| CTX120 | Multiple myeloma | Allogeneic CAR-T | Phase 1 |
| CTX130 | Solid tumors | Allogeneic CAR-T | Phase 1 |
| CTX130 | Renal cell carcinoma | Allogeneic CAR-T | Phase 1 |
| VCTX1 | Type 1 Diabetes | Regenerative | Preclinical |
| CTX110 | Sickle cell disease | Autologous ex vivo | Phase 1 |
| Year | Milestone |
|---|---|
| 2013 | Company founded by Emmanuelle Charpentier |
| 2016 | IPO on NASDAQ |
| 2018 | First IND submission (CTX001 with Vertex) |
| 2020 | Positive Phase 1 data for CTX001 (sickle cell) |
| 2023 | FDA approval of Casgevy for sickle cell disease |
| 2024 | Multiple CAR-T programs in clinical trials |
| Company | Technology | Focus |
|---|---|---|
| Editas Medicine | CRISPR/Cas9 | In vivo editing |
| Intellia Therapeutics | CRISPR/Cas9 | LNP delivery |
| Caribou Biosciences | CRISPR/Cas9 | Off-the-shelf CAR-T |
| Beam Therapeutics | Base editing | Precise editing |
In December 2023, the FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy for sickle cell disease:
CRISPR Gene Editing
Gene Therapy Gene Therapy for Neurological Diseases
Companies Index
Alzheimer's Disease Pipeline Companies](/diseases/alzheimers-disease)
Parkinson's Disease Pipeline Companies](/genes/ar)
Casgevy FDA Approval (2023). 2023. ↩︎
Pipeline Overview (2024). 2024. ↩︎
Vertex Partnership (2015). 2015. ↩︎